LIFESCI new note $BLU interesting takeaways from discussion with MGT 1) based on PK profile, BLU-5937 is expected to have similar kinetics of response to gefapxiant,which had activity within hours of first dose - $MRK &amp;Shionogi est that there are 5&amp; 6 million patients in US, https://t.co/zIDFMsY5rf